Pulmonary Arterial Hypertension Drugs
May 27, 2025
Gilead’s TRODELVY Shows PFS Benefit in 1L Metastatic TNBC; Otsuka’s Sibeprenlimab Gets FDA Priority Review for IgA Nephropathy; Liquidia Wins FDA Nod for YUTREPIA in PAH and PH-ILD; GSK’s BLENREP Combos Get CHMP Backing in Myeloma; Relief Therapeutics Receives FDA Rare Pediatric Disease Tag for RLF-TD011
Gilead’s TRODELVY Demonstrates Significant PFS Benefit in First-Line Metastatic TNBC in ASCENT-03 Trial Gilead Sciences has announced positive topline results from the Phase III ASCENT-03 trial of TRODELVY (sacituzumab govitecan-hziy) in first-line metastatic triple-negative breast cancer (mTNBC) patients who ar...
Read More...
Jun 17, 2024
WINREVAIR Approval for Pulmonary Arterial Hypertension Treatment: Is It A Game-Changer for Merck?
Merck’s investment of $11.5 billion in acquiring Acceleron Pharma is expected to yield significant returns with the FDA’s approval of WINREVAIR (sotatercept), a pivotal component of the acquisition, for the treatment of pulmonary arterial hypertension. An estimated prevalence of pulmonary hypertension at the pop...
Read More...
Jan 28, 2020
Acceleron Pharma’s drug sotatercept touches the phase 2 mark; GT Medical receives nod for GammaTile; New treatment strategy for Parkinson’s disease
The drug, sotatercept of Acceleron Pharma, touches the phase 2 mark Acceleron Pharma, a clinical-stage biopharmaceutical company based in Boston, Massachusetts with a primary aim on the development of medicines that regulate the transforming growth factor-beta (TGF-β) superfamily of proteins that play significan...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
